Methisoprinol (Inosine Pranobex) for Mumps During a Local Outbreak: Findings from a Descriptive Single-Center Study
DOI:
https://doi.org/10.30659/medali.7.2.103-108Keywords:
Paramyxovirus, Mumps, Methisiprinol, Inosine PranobexAbstract
Background: Mumps is an acute infectious disease caused by the paramyxovirus, commonly found in many countries. In 2024, mumps outbreaks were reported globally, with significant cases in India (18,158), the USA (328), the Netherlands (578), and Indonesia (413). The current treatment guidelines for mumps are paracetamol or ibuprofen for pain relief. Purpose: To describe clinical profiles and outcomes of mumps patients treated with methisoprinol in a single-center cross-sectional study. Methods: A descriptive cross-sectional study of mumps patients treated with methisoprinol was conducted at the Islamic Dental Hospital Sultan Agung, Semarang, using retrospective data from August to December 2024. Mumps was defined by the WHO's clinical definition of parotid gland swelling. Results: Among 35 mumps patients, there was an almost equal gender distribution, with most being under 18. The majority had a history of febrile illness, used symptomatic medication, and lacked MMR vaccination history. There was a significant difference in the duration of parotitis before and after methisoprinol medication. Factors like sex, age, parotitis location, and MMR vaccination history did not significantly affect recovery time. Conclusion: Methisoprinol significantly reduced the duration of parotitis, while sex, age, parotitis location, and MMR vaccination history did not significantly influence recovery time.
References
CDC. Mumps Cases and Outbreaks [Internet]. Centers for Disease Control and Prevention. 2024 [cited 2024 Dec 23]. Available from: https://www.cdc.gov/mumps/outbreaks/index.html#cdc_data_surveillance_section_2-reported-u-s-mumps-cases-by-jurisdiction-2024
WHO South-East Asia Region. Epidemiological Bulletin 7th Edition. World Health Organization. 2024 Apr;1–13.
RIVM. Current figures on mumps in the Netherlands [Internet]. Dutch National Institute for Public Health and the Environment. 2024 [cited 2024 Dec 23]. Available from: https://www.rivm.nl/en/mumps/current-figures
Ministry of Health Republic Indonesia. Alertness to the rise of mumps cases. Jakarta; 2024.
WHO. Mumps [Internet]. World Health Organization. 2024 [cited 2024 Dec 23]. Available from: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccine-standardization/mumps
Boyle C, Asimakopoulos P, Khatamzas E, Vernham G. Mumps presenting with unilateral, synchronous parotid and submandibular gland swelling. BMJ Case Rep. 2018;2018:1–4.
Grennan D. Outbreaks ofmumps in the United States have increased since 2006. JAMA. 2019;322(10):2019.
Srinivasan S, Torres AG, Ribas de Pouplana L. Inosine in Biology and Disease. Genes (Basel) [Internet]. 2021 Apr 19;12(4):600. Available from: https://pubmed.ncbi.nlm.nih.gov/33921764
Beran J, Špajdel M, Katzerová V, Holoušová A, Malyš J, Finger Rousková J, et al. Inosine Pranobex Significantly Decreased the Case-Fatality Rate among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens. 2020;9(12).
Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther [Internet]. 2019;36(8):1878–905. Available from: https://doi.org/10.1007/s12325-019-00995-6
Beran J, Šalapová E, Špajdel M, Team on behalf of the IS (EWO I 2014/1). Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis [Internet]. 2016;16(1):648. Available from: https://doi.org/10.1186/s12879-016-1965-5
Kaczmarczyk D, Zagacki D, Morawiec-Sztandera A. Upper respiratory tract infection in children – immunostimulating treatment. J Educ Heal Sport [Internet]. 2021 Sep 6;11(9 SE-Review Articles):80–9. Available from: https://apcz.umk.pl/JEHS/article/view/JEHS.2021.11.09.011
Lasek W, Janyst M, Wolny R, Zapała Ł, Bocian K, Drela N. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes. Acta Pharm [Internet]. 2015;65(2):171–80. Available from: https://doi.org/10.1515/acph-2015-0015
Janíčková O, Ancičová L, Briestenská K, Mistríková J. The effect of isoprinosine treatment on persistent infection of Balb/c mice infected with murine gammaherpesvirus 68. Acta Virol. 2017;61(1):32–8.
Kim IS, Jo EK. Inosine: A bioactive metabolite with multimodal actions in human diseases. Front Pharmacol [Internet]. 2022;13. Available from: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1043970
Kushner LE, Kamens J, Bertaina A, Shyr D, Gans HA. Vaccine Associated Measles Complicated by Suspected Measles Inclusion Body Encephalitis in a Pediatric Leukemia Patient and Stem Cell Transplant Recipient: A Focus on Clinical Evolution and Management. Pediatr Infect Dis J [Internet]. 2024;43(6). Available from: https://journals.lww.com/pidj/fulltext/2024/06000/vaccine_associated_measles_complicated_by.20.aspx
Tuncel D, Ozbek AE, Demirpolat G, Karabiber H. Subacute Sclerosing Panencephalitis with Generalized Seizure as a First Symptom: A Case Report. Jpn J Infect Dis. 2006;59(5):317–9.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
This work is licensed under a Creative Commons Attribution 4.0 International License.
